"10.1371_journal.pone.0013137","plos one","2010-10-04T00:00:00Z","Pablo D Becker; Nicolas Legrand; Caroline M M van Geelen; Miriam Noerder; Nicholas D Huntington; Annick Lim; Etsuko Yasuda; Sean A Diehl; Ferenc A Scheeren; Michael Ott; Kees Weijer; Heiner Wedemeyer; James P Di Santo; Tim Beaumont; Carlos A Guzman; Hergen Spits","Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research (HZI), Braunschweig, Germany; Department of Cell Biology and Histology, Academic Medical Center of the University of Amsterdam (AMC-UvA), Center for Immunology Amsterdam (CIA), Amsterdam, The Netherlands; AIMM Therapeutics, Amsterdam, The Netherlands; Cytokines and Lymphoid Development Unit, Institut Pasteur, Paris, France; INSERM U668, Institut Pasteur, Paris, France; Clinic for Gastroenterology, Hepatology, and Endocrinology, Hannover Medical School, Twincore Centre of Experimental and Clinical Infection Research, Hannover, Germany","Conceived and designed the experiments: PDB NL CMMvG. Performed the experiments: PDB NL CMMvG MN NH AL EY SAD FAS. Analyzed the data: PDB NL CMMvG NH AL MO HW JPDS TB CAG HS. Contributed reagents/materials/analysis tools: KW. Wrote the paper: PDB NL CMMvG NH JPDS TB CAG HS.","F.A.S., S.A.D., T.B. and H.S. are listed on a patent application describing the BCL6/BCL-XL technology developed by AIMM Therapeutics. C.M.M.v.G., E.Y., T.B. and H.S. are employees of AIMM Therapeutic. The employees of AIMM Therapeutics all have equity interest. H.S. has personal financial interests in AIMM Therapeutics. This does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials. The other authors have no conflicting financial interests.","2010","10","Pablo D Becker","PDB",16,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
